Car manufacturers begin offering insurance to support sales.

Insurers and sponsors tasked with funding new drugs or limiting their usage.

Rates are going up, but trend may be moderated or mitigated by regulation.

Analysts report on the implications for insurers.

Recent deterioration has negative impact on earnings; capital levels not affected.

Illiquidity, complexity, model risk and counterparty risks examined in new research note.

Slower transition in Canada gives insurers opportunity to learn from European experience.